Cardio Diagnostics Holdings, Inc. (CDIO) Research

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.

Market snapshot

Symbol
CDIO
Price
$1.98
Day change
0.00%
Market cap
$4.1M
P/E ratio
-0.85x
52-week range
0.97-7.91
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Adial Pharmaceuticals, Inc. (ADIL)
  • Addex Therapeutics Ltd (ADXN)
  • BioCardia, Inc. (BCDA)
  • Brainstorm Cell Therapeutics Inc. (BCLI)
  • Creative Medical Technology Holdings, Inc. (CELZ)
  • Impact BioMedical Inc. (IBO)
  • Matinas BioPharma Holdings, Inc. (MTNB)
  • NeuroSense Therapeutics Ltd. (NRSN)

Recent insider activity

  • Fung Peter K — A-Award (3205 shares) on 2026-03-31
  • Betts Wendy J — A-Award (3205 shares) on 2026-03-31
  • Intrater James — A-Award (3205 shares) on 2026-03-31
  • Burton Paul Frederick — A-Award (3205 shares) on 2026-03-31
  • Fung Peter K — A-Award (2306 shares) on 2025-12-31

Open Cardio Diagnostics Holdings, Inc. (CDIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.